A client taking mavacamten for obstructive hypertrophic cardiomyopathy reports new dyspnea and ankle edema. Review the record and select the priority action.
Chart/Exhibit
Choose your responses, then check the answer.
Explanation
New heart-failure symptoms with an LVEF below 50% require mavacamten interruption and prompt evaluation. A newly added CYP3A4 inhibitor can increase exposure and worsen systolic dysfunction.
Quick answer Link new dyspnea, LVEF 47%, and a CYP inhibitor to mavacamten-related systolic dysfunction.
Why this is correct Mavacamten reduces cardiac myosin activity and can cause heart failure from systolic dysfunction. The labeled monitoring pathway uses symptoms, echocardiography, and interaction review to determine interruption and safe resumption.
Easy analogy or mental picture Build a medication-safety chain: identify the new cue, connect it to the drug mechanism or labeled limitation, stop preventable exposure, stabilize the client, and verify a measurable response.
Memory hook Drug, urgent cue, protective action, and reassessment endpoint.
NCLEX decision rule Choose the action that prevents the most immediate medication-related harm while preserving indicated treatment and required monitoring.
Why the other choices are wrong Options that continue a suspect exposure, normalize a labeled danger cue, substitute an unauthorized dose, or delay escalation leave the client at risk.
Medication-safety reviewVerify indication, current assessment, dose and route, organ function, interactions, urgent toxicity cues, authorized action, and measurable follow-up.